RELF IIa: The Accuracy of the Mini RELF Device for the Diagnosis of an Acute Coronary Artery Occlusion.

Sponsor
University Ghent (Other)
Overall Status
Completed
CT.gov ID
NCT02983396
Collaborator
(none)
64
3
1
17
21.3
1.3

Study Details

Study Description

Brief Summary

Patient delay in seeking medical attendance for symptoms of acute ST elevation myocardial infarction (STEMI) is the major obstacle to reduce the current mortality from acute coronary syndromes. The Mini RELF device is a hand held self applicable device intended to detect on an individual basis an elevation of the ST segment that is indicative for an acute coronary occlusion. The investigators aim to evaluate the accuracy of Mini RELF device when it is self-applied on a daily basis by patients with coronary artery disease.

Condition or Disease Intervention/Treatment Phase
  • Device: Diagnostic accuracy of Mini Relf Device
N/A

Detailed Description

The increasing availability of small hand held medical devices is a novel opportunity to develop a tool that guides patients through the decision-taking processes of seeking medical attendance during symptoms suggestive of acute myocardial infarction. The cornerstone of early diagnosis, risk stratification and treatment is the presence of ST segment elevation during symptoms suggestive of STEMI. Therefore, a hand held medical device that can detect ST segment elevation with high sensitivity and specificity could be a breakthrough in the further reduction of fatality from acute myocardial infarction. A number of conditions of the tool must be fulfilled to allow save use with a low threshold in the general population. Most important is the accuracy to detect any new ST segment elevation related to an acute artery occlusion. For more than 30 years the 12-lead ECG is the gold standard for detection of ST elevation. However, acute coronary occlusions of a posterior or lateral segment are not always detected by the gold standard. Moreover, in the very early phase of acute coronary occlusion, the accuracy 12 lead ECG is inadequate.

In a previous study "Diagnostic accuracy of a novel method for detection of acute transmural myocardial ischemia based upon a self-applicable 3-lead configuration" the investigators developed and validated a sensitive and specific 3-lead ECG method (RELF method). The method includes a new lead configuration and a new algorithm to analyze the ECG recordings based on an intra-individual comparisons of ST levels. In summary, a 3-lead recording from a healthy subject or from a patient with an acute coronary occlusion is compared automatically to one or more previous reference recordings from the same individual. The individualized ST shift is used as a decision variable to detect or reject an acute coronary artery occlusion. The RELF method was more accurate then the simultaneously applied 12-lead ECG which had a lower sensitivity and specificity. In that study all recordings were performed by a sophisticated ECG recording system. The RELF method is designed to be applicable also by small hand held ECG devices such as the self-applicable Mini RELF device.

In the current study the investigators aim to evaluate the accuracy of Mini RELF device relative to the 12 lead ECG when the device is self-applied on a daily basis by patients with coronary artery disease. In a parallel study (RELF IIb) the investigators aim to evaluate the specificity of the RELF method when it is self-applied by healthy subjects who are representative for future users of the device.

Study Design

Study Type:
Interventional
Actual Enrollment :
64 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
The Accuracy of the Mini RELF Device Relative to the 12 Lead ECG for the Diagnosis of an Acute Coronary Artery Occlusion in Patients With Coronary Artery Disease.
Actual Study Start Date :
Nov 18, 2016
Actual Primary Completion Date :
Apr 19, 2018
Actual Study Completion Date :
Apr 19, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: no transmural ischemia (NTI) and transmural ischemia (TI)

Case cross-over from "no transmural ischemia (NTI)" to "transmural ischemia at 60 s coronary occlusion during elective coronary angioplasty (TI)" Comparison of diagnostic accuracy of standard 12-lead ECG versus Mini RELF device for detection of transmural ischemia.

Device: Diagnostic accuracy of Mini Relf Device
Evaluation of the Mini Relf Device when it is applied on daily basis at home and during coronary angioplasty at 60 second acute coronary occlusion angioplasty

Outcome Measures

Primary Outcome Measures

  1. The accuracy (Area under the sensitivity-aspecificity curve) of Modus RELF-2 (The orthonormalized ST shift vector magnitude) [One week after coronary angioplasty]

    The sensitivity and specificity of the orthonormalized ST shift vector magnitude during occlusion compared to the sensitivity and specificity of the 12 lead ECG.

Secondary Outcome Measures

  1. The accuracy (Area under the sensitivity-aspecificity curve) of Modus RELF-3 [One week after coronary angioplasty]

    The sensitivity and specificity of the intraindividual orthonormalized ST shift vector magnitude

  2. The accuracy (Area under the sensitivity-aspecificity curve) of Modus RELF-1 (The gender specific orthonormalized ST vector magnitude) and of Modus RELF-3 (The intra-individual orthonormalized ST shift vector magnitude). [One week after coronary angioplasty]

    The sensitivity and specificity of the gender specific orthonormalized ST vector magnitude and the intra-individual orthonormalized ST shift vector magnitude during occlusion compared to the sensitivity and specificity of the 12 lead ECG.

  3. Number of participants with symptoms of contact dermatitis in the thoracic device-skin contact area. [One week after coronary angioplasty]

    Contact dermatitis is defined by the clinical presence of redness or itching or blistering delineated in the thoracic device-skin contact area during at least one of the three clinical visits in the study participation period.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients who have an appointment for an elective coronary angioplasty.
Exclusion Criteria:
  • Patients with coronary artery bypass grafts.

  • Patients with implanted pacemaker or ICD.

  • Patients who remain hospitalized until the planned angioplasty.

  • Patient who are unfamiliar with use of smart phone. The test question "did you use by yourself a smart phone to make a telephone call in the last 4 weeks" should be answered by yes.

  • Patients who cannot tolerate repetitive applications of standard skin electrodes on the chest.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Algemeen Ziekenhuis Sint-Jan Brugge Brugge Belgium 8000
2 University Hospital Ghent Ghent Belgium 9000
3 AZ Sint Nikolaas Sint-Niklaas Belgium 9100

Sponsors and Collaborators

  • University Ghent

Investigators

  • Study Chair: Peter Gheeraert, Professor, University Ghent, Belgium

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Ghent
ClinicalTrials.gov Identifier:
NCT02983396
Other Study ID Numbers:
  • UniversityGhent
First Posted:
Dec 6, 2016
Last Update Posted:
Dec 10, 2021
Last Verified:
Dec 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by University Ghent
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 10, 2021